vs

Side-by-side financial comparison of BADGER METER INC (BMI) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $234.1M, roughly 1.4× BADGER METER INC). BADGER METER INC runs the higher net margin — 14.3% vs -18.2%, a 32.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 14.1%). BADGER METER INC produced more free cash flow last quarter ($50.8M vs $-133.8M).

Badger Meter Inc. is a leading global provider of flow measurement and control solutions, serving water utilities, industrial, commercial, and residential customer segments. Its core offerings include smart water meters, IoT-enabled usage monitoring systems, and supporting software that help clients track resource consumption, cut waste, and boost operational efficiency, with key markets spanning North America, Europe, and the Asia-Pacific region.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

BMI vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.4× larger
MDGL
$321.1M
$234.1M
BMI
Growing faster (revenue YoY)
MDGL
MDGL
+196.6% gap
MDGL
210.8%
14.1%
BMI
Higher net margin
BMI
BMI
32.6% more per $
BMI
14.3%
-18.2%
MDGL
More free cash flow
BMI
BMI
$184.6M more FCF
BMI
$50.8M
$-133.8M
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BMI
BMI
MDGL
MDGL
Revenue
$234.1M
$321.1M
Net Profit
$33.6M
$-58.6M
Gross Margin
39.7%
Operating Margin
18.4%
-18.6%
Net Margin
14.3%
-18.2%
Revenue YoY
14.1%
210.8%
Net Profit YoY
9.3%
1.4%
EPS (diluted)
$1.13
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMI
BMI
MDGL
MDGL
Q4 25
$234.1M
$321.1M
Q3 25
$222.2M
$287.3M
Q2 25
$238.1M
$212.8M
Q1 25
$222.2M
$137.3M
Q4 24
$205.2M
$103.3M
Q3 24
$208.4M
$62.2M
Q2 24
$216.7M
Q1 24
$196.3M
$0
Net Profit
BMI
BMI
MDGL
MDGL
Q4 25
$33.6M
$-58.6M
Q3 25
$35.1M
$-114.2M
Q2 25
$34.6M
$-42.3M
Q1 25
$38.4M
$-73.2M
Q4 24
$30.7M
$-59.4M
Q3 24
$32.0M
$-107.0M
Q2 24
$33.1M
Q1 24
$29.1M
$-147.5M
Gross Margin
BMI
BMI
MDGL
MDGL
Q4 25
39.7%
Q3 25
43.1%
Q2 25
41.1%
Q1 25
42.9%
96.7%
Q4 24
40.3%
Q3 24
40.2%
Q2 24
39.4%
Q1 24
39.3%
Operating Margin
BMI
BMI
MDGL
MDGL
Q4 25
18.4%
-18.6%
Q3 25
20.7%
-39.7%
Q2 25
18.8%
-22.2%
Q1 25
22.2%
-57.8%
Q4 24
19.1%
-64.8%
Q3 24
19.5%
-187.1%
Q2 24
19.2%
Q1 24
18.6%
Net Margin
BMI
BMI
MDGL
MDGL
Q4 25
14.3%
-18.2%
Q3 25
15.8%
-39.8%
Q2 25
14.5%
-19.9%
Q1 25
17.3%
-53.4%
Q4 24
15.0%
-57.5%
Q3 24
15.4%
-172.0%
Q2 24
15.3%
Q1 24
14.8%
EPS (diluted)
BMI
BMI
MDGL
MDGL
Q4 25
$1.13
$-2.55
Q3 25
$1.19
$-5.08
Q2 25
$1.17
$-1.90
Q1 25
$1.30
$-3.32
Q4 24
$1.04
$-2.50
Q3 24
$1.08
$-4.92
Q2 24
$1.12
Q1 24
$0.99
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMI
BMI
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$713.3M
$602.7M
Total Assets
$973.6M
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMI
BMI
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$295.7M
Q2 25
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$232.7M
Q2 24
Q1 24
$622.5M
Total Debt
BMI
BMI
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
BMI
BMI
MDGL
MDGL
Q4 25
$713.3M
$602.7M
Q3 25
$702.5M
$625.7M
Q2 25
$677.6M
$696.0M
Q1 25
$641.7M
$710.6M
Q4 24
$606.2M
$754.4M
Q3 24
$591.2M
$777.2M
Q2 24
$563.1M
Q1 24
$535.6M
$850.8M
Total Assets
BMI
BMI
MDGL
MDGL
Q4 25
$973.6M
$1.3B
Q3 25
$978.3M
$1.4B
Q2 25
$936.4M
$1.0B
Q1 25
$899.6M
$996.6M
Q4 24
$816.4M
$1.0B
Q3 24
$802.9M
$1.1B
Q2 24
$781.3M
Q1 24
$743.5M
$1.1B
Debt / Equity
BMI
BMI
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMI
BMI
MDGL
MDGL
Operating Cash FlowLast quarter
$54.8M
$-133.5M
Free Cash FlowOCF − Capex
$50.8M
$-133.8M
FCF MarginFCF / Revenue
21.7%
-41.7%
Capex IntensityCapex / Revenue
1.7%
0.1%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters
$169.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMI
BMI
MDGL
MDGL
Q4 25
$54.8M
$-133.5M
Q3 25
$51.3M
$79.8M
Q2 25
$44.6M
$-47.1M
Q1 25
$33.0M
$-88.9M
Q4 24
$52.1M
$-104.5M
Q3 24
$45.1M
$-67.0M
Q2 24
$36.4M
Q1 24
$21.5M
$-149.2M
Free Cash Flow
BMI
BMI
MDGL
MDGL
Q4 25
$50.8M
$-133.8M
Q3 25
$48.2M
$79.0M
Q2 25
$40.6M
Q1 25
$30.1M
Q4 24
$47.4M
$-104.7M
Q3 24
$42.0M
$-67.8M
Q2 24
$34.1M
Q1 24
$18.8M
$-149.5M
FCF Margin
BMI
BMI
MDGL
MDGL
Q4 25
21.7%
-41.7%
Q3 25
21.7%
27.5%
Q2 25
17.1%
Q1 25
13.5%
Q4 24
23.1%
-101.3%
Q3 24
20.1%
-109.0%
Q2 24
15.7%
Q1 24
9.6%
Capex Intensity
BMI
BMI
MDGL
MDGL
Q4 25
1.7%
0.1%
Q3 25
1.4%
0.3%
Q2 25
1.7%
0.0%
Q1 25
1.3%
0.0%
Q4 24
2.3%
0.2%
Q3 24
1.5%
1.3%
Q2 24
1.1%
Q1 24
1.4%
Cash Conversion
BMI
BMI
MDGL
MDGL
Q4 25
1.63×
Q3 25
1.46×
Q2 25
1.29×
Q1 25
0.86×
Q4 24
1.70×
Q3 24
1.41×
Q2 24
1.10×
Q1 24
0.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BMI
BMI

Transferred At Point In Time$198.6M85%
Transferred Over Time$22.1M9%
Other$13.4M6%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons